Drug Development

EU Regulator Recommends AstraZeneca’s Low-Carbon COPD Inhaler

The CHMP’s positive opinion sets the stage for final EU Commission approval to replace high-global-warming-potential propellant with Honeywell’s lower-carbon alternative throughout AstraZeneca’s regional supply